Proteasome Inhibitors Market: Key Drivers, Insights, Outlook, Overview, and Research Report 2024-2033

"The new report published by The Business Research Company, titled Proteasome Inhibitors Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the proteasome inhibitors market size has grown strongly in recent years. It will grow from $1.86 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The proteasome inhibitors market size is expected to see strong growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12251&type=smp

Proteasome Inhibitors Market Fuels With Focus On Pancreatic Cancer
The increasing prevalence of pancreatic cancer is expected to propel the growth of the proteasome inhibitors market going forward. Pancreatic cancer is a type of cancer that develops in the cells of the pancreas, an organ located in the abdomen behind the stomach. Proteasome inhibitors are primarily used to treat pancreatic cancer, where proteasome plays a critical role in promoting cell survival and growth by degrading proteins that regulate cell cycle progression and cell death. It disrupts cancer cell survival and inhibits tumor growth and metastasis. For instance, in March 2023, according to the reports by the American Society of Clinical Oncology (ASCO), a US-based professional organization for oncology professionals, an estimated 64,050 adults in the US were diagnosed with pancreatic cancer by 2023, and 50,550 people died of pancreatic cancer. Furthermore, globally, 495,773 people were diagnosed, and 466,003 died of pancreatic cancer in 2020. Therefore, the increasing prevalence of pancreatic cancer is driving the growth of the proteasome inhibitors market.

Strategic Funding Initiatives For Advancing Research
Increases in investments are a key trend gaining popularity in the proteasome inhibitors market. Major companies operating in the proteasome inhibitors market are investing in developing and commercializing proteasome inhibitors, which can play a significant role in advancing research and bringing new treatments to the market. For instance, in September 2022, QLi5 Therapeutics GmbH, a Germany-based developer of new-class proteasome inhibitors, received $10.96 million (EUR 10 million) of investments from SV Investment, a South Korea-based venture capital firm, and KHAN Technology Transfer Fund I, a Germany-based venture capital firm, as well as Atinum Investment Co., Ltd. and Daol Investment & Securities Co., Ltd., South Korea-based venture capital firms. This investment aims to develop novel proteasome inhibitors for treating cancer and inflammatory and autoimmune disorders. With the help of this funding, QLi5's pipeline of very distinct proteasome inhibitors will be advanced to the beginning of clinical studies addressing multiple indications.

The proteasome inhibitors market covered in this report is segmented -

1) By Product: Velcade, Kyprolis, Ninlaro, Other Products
2) By Drugs: Bortezomib, Carfilzomib, Ixazomib
3) By Indication: Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospital, Specialty Clinics, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12251&type=discount

Major companies operating in the proteasome inhibitors market report are Pfizer Inc., Johnson And Johnson, AbbVie, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Fresenius Kabi AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Sigma-Aldrich, Zydus Pharmaceuticals, Onyx Pharmaceuticals Inc., Tocris Bioscience, Accuitis Inc., TG Therapeuticsn Inc., QLi5 Therapeutics GmbH, Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Lifesensors Inc., MimiVax LLC, Apotex Inc.

Contents of the report:
1. Executive Summary
2. Proteasome Inhibitors Market Report Structure
3. Proteasome Inhibitors Market Trends And Strategies
4. Proteasome Inhibitors Market - Macro Economic Scenario
5. Proteasome Inhibitors Market Size And Growth
…..
27. Proteasome Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide. "

This release was published on openPR.